Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.
Search results for:

dihydroergotamine

dihydroergotamine
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Brekiya INJECTION, SUBCUTANEOUS 1 mg/mL      
D.H.E. 45 SOLUTION, INJECTABLE 1 mg/mL      
Migranal, DHE Nasal, Atzumi SPRAY, NASAL 4 mg/mL, 5.2 mg      
VIEW MORE Sympatholytic (Adrenergic Blocking) Agents, Antimigraine Agents
Comments:

If nasal spray ordered, contact prescriber to discuss alternative formulary agents (DHE injection or ergotamine SL tab).

Brekiya (DHE autoinjector): Non-Formulary. Inpatients may use home supply or contact prescriber to discuss alternative formulary agents.

 

Reviewed: January 2017 (Pediatrics), January 2017, January 2026 (Brekiya), July 2026 (Atzumi)

Dihydroergotamine Mesylate (BREKIYA) Specialty Drug Summary.pdf

Last updated: Jul. 23, 2026
Rhazdrugs dihydroergotamine






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2026 Rpharmy, LLC ­ All Rights Reserved